Oragenics, Inc. (OGEN)
NYSEAMERICAN: OGEN · Real-Time Price · USD
0.9582
-0.0118 (-1.22%)
Jan 21, 2026, 10:22 AM EST - Market open
Oragenics Employees
Oragenics had 5 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
5
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$2,180,948
Market Cap
3.99M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 5 | 0 | - | 3 | 2 |
| Dec 31, 2023 | 5 | -1 | -16.67% | 5 | 0 |
| Dec 31, 2022 | 6 | 1 | 20.00% | 6 | 0 |
| Dec 31, 2021 | 5 | -2 | -28.57% | 5 | 0 |
| Dec 31, 2020 | 7 | 0 | - | 7 | 0 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| BiomX | 57 |
| Jaguar Health | 49 |
| Lyra Therapeutics | 30 |
| Psyence Biomedical | 12 |
| Enveric Biosciences | 6 |
| Galmed Pharmaceuticals | 6 |
| XORTX Therapeutics | 3 |
| Matinas BioPharma Holdings | 3 |
OGEN News
- 2 months ago - Oragenics Q3 2025 Shareholder Update - Business Wire
- 3 months ago - Oragenics Regains Full NYSE American Compliance, Company Resolves Stockholder Equity Deficiency - Business Wire
- 3 months ago - Oragenics Announces Strategic Partnership with Receptor.AI to Accelerate Pipeline Development - Business Wire
- 5 months ago - Oragenics Q2 2025 Shareholder Update - GlobeNewsWire
- 6 months ago - Oragenics, Inc. Announces U.S.-Based Drug Manufacturing Agreement to Support ONP-002 Clinical Development - GlobeNewsWire
- 7 months ago - Oragenics Completes Approximately $16.5 Million Offering - GlobeNewsWire
- 7 months ago - Oragenics, Inc. Announces Pricing of Public Offering of up to $20 Million of Preferred Stock and Warrants - GlobeNewsWire
- 9 months ago - Oragenics, Inc. Announces Approval to Initiate Phase II Concussion Drug Trial in Australia - GlobeNewsWire